Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.